美诺华 (603538)

Ningbo Menovo Pharmaceutical Co., Ltd.

ASH

Tags

Contract Research Organization (CXO)QFII Heavy PositionsWeight Loss DrugsChemical PharmaceuticalsPharmaceutical ManufacturingPharmaceuticals and HealthcareSynthetic BiologyContains Convertible BondsPet EconomyHepatitis ConceptMargin Trading and Securities LendingAssisted Reproduction医药生物

K-Line Chart

No K-line data available

Company NameNingbo Menovo Pharmaceutical Co., Ltd.
Listing Date2017-04-07
Issue Price14.03RMB
Registered Capital21982.826710k RMB
Legal RepresentativeYao Chengzhi
Registered AddressRoom 1406, No. 1, Lane 999, Yangfan Road, High-tech Zone, Ningbo City, Zhejiang Province
IndustryChemical Pharmaceuticals
Main BusinessR&D, production, and sales of specialty active pharmaceutical ingredients (APIs) and pharmaceutical intermediates.
Company ProfileNingbo Menovo Pharmaceutical Co., Ltd. (hereinafter referred to as "Menovo", stock code: 603538) was founded in 2004. It is a comprehensive pharmaceutical enterprise integrating the R&D, pilot-scale testing, production, and sales of pharmaceutical intermediates, active pharmaceutical ingredients (APIs), and finished dosage forms. Headquartered in Ningbo National Hi-tech Industrial Development Zone, it has 7 wholly-owned subsidiaries in Anhui and Zhejiang, 3 strategic holding companies, 1 Sino-European joint venture pharmaceutical company, 2 provincial-level drug research institutes (technology centers), and 3 formulation R&D centers. It has established offices in India, the United States, the European Union, and other regions. Menovo is ranked among the Top 100 Manufacturing and Most Competitive Enterprises in Ningbo City and the Top 10 Pharmaceutical Industrial Enterprises. Its total assets exceed RMB 2 billion, and it currently employs over 1,900 staff. The company was listed on the Main Board of the Shanghai Stock Exchange on April 7, 2017.

Stock Details

1. Key Indicators

  • Total Shares(W): 22061.83
  • Circulating A-Shares(W): 21618.29
  • Earnings Per Share(RMB): 0.4300
  • Net Assets Per Share(RMB): 10.1859
  • Operating Revenue(W RMB): 111679.36
  • Total Profit(W RMB): 11817.84
  • **Net Profit Attributable to Parent(W RMB) **: 9592.54
  • Net Profit Growth Rate(%): 51.66
  • Weighted Return on Equity(%): 4.2600
  • Operating Cash Flow Per Share(RMB): 0.1450
  • Undistributed Profit Per Share(RMB): 6.1551
  • Capital Reserve Per Share(RMB): 3.0514

2. Main Business

The main business covers:

  • Research, production, and sales of specialty active pharmaceutical ingredients (APIs) and pharmaceutical intermediates.

3. Company Basic Information

  • Company Name: Ningbo Menovo Pharmaceutical Co., Ltd.
  • Listing Date: 2017-04-07
  • Industry: Pharmaceutical Manufacturing
  • Address: Room 1406, No. 1, Lane 999, Yangfan Road, High-tech Zone, Ningbo City, Zhejiang Province
  • Website: https://www.menovopharm.com
  • Company Profile: The issuer was established as a joint stock limited company through the overall change of Menovo Pharmaceutical Co., Ltd. On January 10, 2012, Menovo Pharmaceutical Co., Ltd. held a shareholders' meeting and agreed to change the company into a joint stock limited company. According to the "Audit Report" (Xin Hui Shi Bao Zi [2012] No. 110020) issued by Lixin Certified Public Accountants, the net assets of the limited company as of December 31, 2011, were RMB 267,624,738.15. This amount was converted into 90 million shares at a ratio of approximately 1:0.3363, with a par value of RMB 1 per share, all of which are ordinary shares. The total share capital of the joint stock company was RMB 90 million, and the portion not included in the share capital, RMB 177,624,738.15, was recorded as the company's capital reserve. On January 12, 2012, Lixin Certified Public Accountants verified the receipt of the registered capital when the issuer was changed to a joint stock limited company and issued the "Capital Verification Report" (Xin Hui Shi Bao Zi [2012] No. 110079). On January 30, 2012, the joint stock company held its founding meeting, reviewed and adopted the "Company Articles of Association," and elected the first board of directors and board of supervisors. On February 14, 2012, the joint stock company was registered and established with the Ningbo Municipal Administration for Market Regulation in Zhejiang Province, with a registration number of 330215000002952 and a registered capital and share capital of RMB 90 million.

4. Top 10 Circulating Shareholders

Rank Institution Name Institution Type Shares Held (W) Percentage Held (%)
1 Ningbo Menovo Pharmaceutical Holding Group Co., Ltd. Corporate Legal Person 4528.57 20.95
2 J. P. Morgan Securities PLC - Proprietary Funds QFII 186.10 0.86
3 Xinhua Preferred Dividend Hybrid Securities Investment Fund - Class A Fund 131.29 0.61
4 CITIC Securities Asset Management (Hong Kong) Limited - Client Funds Asset Management Plan 130.84 0.61
5 UBS AG QFII 92.63 0.43
6 Xinhua Strategy Select Stock Securities Investment Fund - Class A Fund 84.97 0.39
7 Fuanda Pharmaceutical Innovation Mixed Securities Investment Fund Fund 23.55 0.11
8 Fuanda Healthy Life Flexible Allocation Mixed Securities Investment Fund - Class A Fund 9.97 0.05
9 Xinhua Industry Leading Theme Stock Securities Investment Fund Fund 4.68 0.02
10 CITIC Securities Construction Investment Shuangxin Bond Securities Investment Fund - Class A Fund 0.16 0.00

5. Concept Sectors

  • Convertible Bonds
  • CXO Concept
  • Assisted Reproduction
  • Hepatitis Concept
  • Weight Loss Drugs
  • Synthetic Biology
  • Pet Economy
  • Margin Trading & Securities Lending
  • QFII Heavy Holdings

Remarks

  • Data update date: 2025-09-30
  • Data source: Public Market Information